Asset sale Completed
Axsome Therapeutics acquisition of Exclusive global rights to TAK-063 (balipodect)
Advisers
Exclusive global rights to TAK-063 (balipodect)
Target
Not disclosed
Axsome Therapeutics
Acquirer
- Legal adviser
- Target
- Exclusive global rights to TAK-063 (balipodect)
- Acquirer
- Axsome Therapeutics
- Seller
- Takeda Pharmaceutical Co.
- Buyer based in
- United States
- Seller based in
- Japan
- Completed
- 3 Apr 2026
- Sector
- Pharma
- Tags
- Pharma, Drug Development
In the league tables
Similar deals
- Hansoh Pharmaceutical Group Co. stake in Avere Therapeutics Jul 2026 · Biotech
- Tarsus Pharmaceuticals acquisition of iRenix Medical Jul 2026 · US$75m · Ophthalmology
- Adial Pharmaceuticals acquisition of Azora Therapeutics Jun 2026 · Biotech
- Shionogi & Co. acquisition of Shionogi-Apnimed Sleep Science Apr 2026 · US$100m · Pharma
- Amneal Pharmaceuticals acquisition of Kashiv BioSciences Apr 2026 · US$375m · Biotech
